Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circulating Ficolin-2 and Ficolin-3 Form Heterocomplexes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. C1q/TNF-Related Protein 6 Is a Pattern Recognition Molecule That Recruits Collectin-11 from the Complement System to Ligands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term Nonprogressors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Distribution of microcrack surface density in the human otic capsule

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Microcrack surface density in the human otic capsule: An unbiased stereological quantification

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthritis progression in the collagen-induced arthritis (CIA) mouse model to an extent just shy of disease abrogation, but this remarkable observation has not been translated into therapeutic intervention. Our aim was to test the potential in mice of an Ab that blocks the proteolytic capacity of uPA in the CIA model and the delayed-type hypersensitivity arthritis model. A second aim was to determine the cellular origins of uPA and the uPA receptor (uPAR) in joint tissue from patients with rheumatoid arthritis. A mAb that neutralizes mouse uPA significantly reduced arthritis progression in the CIA and delayed-type hypersensitivity arthritis models. In the CIA model, the impact of anti-uPA treatment was on par with the effect of blocking TNF-α by etanercept. A pharmacokinetics evaluation of the therapeutic Ab revealed target-mediated drug disposition consistent with a high turnover of endogenous uPA. The cellular expression patterns of uPA and uPAR were characterized by double immunofluorescence in the inflamed synovium from patients with rheumatoid arthritis and compared with synovium from healthy donors. The arthritic synovium showed expression of uPA and uPAR in neutrophils, macrophages, and a fraction of endothelial cells, whereas there was little or no expression in synovium from healthy donors. The data from animal models and human material provide preclinical proof-of-principle that validates uPA as a novel therapeutic target in rheumatic diseases.

OriginalsprogEngelsk
TidsskriftJournal of immunology (Baltimore, Md. : 1950)
Vol/bind200
Udgave nummer3
Sider (fra-til)957-965
ISSN0022-1767
DOI
StatusUdgivet - 1 feb. 2018

ID: 52347779